* The drug treats excess phosphate in the blood
July 2 Impax Laboratories Inc's (IPXL.O) said
it has filed with U.S. regulators seeking marketing approval
for a generic version of Genzyme Corp's GENZ.O drug Renvela.
The drug treats hyperphosphatemia, or excess phosphate in
the blood, which increases the risk of cardiovascular disease
in patients with chronic kidney disease.
On July 1, Genzyme filed suit for patent infringement
against Impax in a U.S. District Court.
The filing of an abbreviated new drug application (ANDA)
with the U.S Food and Drug Administration includes a paragraph
IV certification for a generic version of Renvela 2.4 g and 0.8
g, the company said in a statement.
Paragraph IV certification gives a 180-day exclusivity to
market a generic to companies that are the "first-to-file" an
Upon regulatory approval, Impax's generic division, Global
Pharmaceuticals, will commercialize the products, the company
Shares of Impax closed at $18.07 Friday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Vyas